Rhenman & Partners Asset Management Ab Has Decreased Its Stake in Adamas Pharmaceuticals INC (ADMS) by $7.33 Million

April 17, 2018 - By Vivian Park

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Logo

Rhenman & Partners Asset Management Ab decreased its stake in Adamas Pharmaceuticals Inc (ADMS) by 24.27% based on its latest 2017Q4 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab sold 222,087 shares as the company’s stock declined 31.02% with the market. The institutional investor held 692,913 shares of the health care company at the end of 2017Q4, valued at $23.48 million, down from 915,000 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Adamas Pharmaceuticals Inc for a number of months, seems to be less bullish one the $676.88M market cap company. The stock increased 3.61% or $0.88 during the last trading session, reaching $25.25. About 269,083 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has risen 35.83% since April 17, 2017 and is uptrending. It has outperformed by 24.28% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $740.07 million US Long portfolio, upped its stake in Sage Therapeutics Inc (NASDAQ:SAGE) by 54,930 shares to 104,930 shares, valued at $17.28M in 2017Q4, according to the filing. It also increased its holding in Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) by 48,436 shares in the quarter, for a total of 133,436 shares, and has risen its stake in Amerisourcebergen Corp (NYSE:ABC).

Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on May, 8. They expect $-1.32 earnings per share, down 83.33 % or $0.60 from last year’s $-0.72 per share. After $-1.27 actual earnings per share reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 3.94 % negative EPS growth.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage

Among 8 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamas Pharmaceuticals had 13 analyst reports since October 30, 2017 according to SRatingsIntel. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) earned “Buy” rating by Piper Jaffray on Tuesday, January 30. Mizuho maintained the shares of ADMS in report on Tuesday, February 20 with “Buy” rating. Evercore maintained the shares of ADMS in report on Tuesday, February 20 with “Buy” rating. The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has “Buy” rating given on Tuesday, January 23 by Mizuho. Piper Jaffray maintained it with “Buy” rating and $49.0 target in Thursday, February 22 report. The company was maintained on Friday, February 23 by Needham. As per Friday, November 3, the company rating was maintained by Mizuho. Noble Financial maintained the stock with “Buy” rating in Wednesday, November 8 report. The stock has “Buy” rating by Northland Capital on Wednesday, November 29. The stock has “Buy” rating by Leerink Swann on Wednesday, April 4.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.